The Biggest Warning Signs That You’re Experiencing Early Menopause
Yana Iskayeva via Getty Images Hormone therapy can be a necessary treatment for some people experiencing early or premature menopause. For half of the population, menopause is something that occurs during middle age and is a sign of the end of the reproductive years. “Menopause is a natural process that occurs in women when their […]
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo for Bladder Cancer
CHICAGO — An oncolytic virus therapy combined with pembrolizumab (Keytruda) produced complete responses (CRs) in 85% of patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), a small phase II trial showed. The results showed CRs in 29 of 34 patients with detectable carcinoma in situ (CIS) treated with cretostimogene grenadenorepvec (CG0070) and the PD-1 […]
Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer
CHICAGO — Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial. After a median follow up of 60.7 months, the combination of enzalutamide and leuprolide acetate ADT demonstrated a 58% reduction in the risk of […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]
Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer
ORLANDO — An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial. Overall, 22 of 23 patients had some degree of PSA decline in response to fractionated […]
What Drives Alzheimer’s in Women?
Female sex, early age at menopause, and hormone therapy use each were associated with higher regional tau in cognitively normal people with elevated beta-amyloid, cross-sectional PET data showed. The highest levels of tau were seen in hormone therapy users who had a delay of more than 5 years between menopause onset and the start of […]
20M People Worldwide Received HIV Treatment Through U.S.-Led Program
Approximately 20 million people with HIV in 54 countries have received antiretroviral therapy (ART) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) as of September 2022, the CDC reported. This represents an increase of 300-fold from the 66,550 reported in September 2004, according to Helen M. Chun, MD, of the Division for Global […]
Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy
SAN FRANCISCO — Add-on hormone therapy plus an antiandrogen to salvage radiation and androgen deprivation therapy (ADT) did not boost survival outcomes in high-risk prostate cancer. In the FORMULA-509 trial, the addition of 6 months of abiraterone acetate (Zytiga) and apalutamide (Erleada) to salvage radiation (RT) and 6 months of ADT with a GnRH agonist […]
Dual Antiplatelet Therapy Proves Mettle in Minor Stroke
DALLAS — Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute minor stroke who presented within 4.5 hours of onset, and had no “clearly disabling deficit,” functional outcome was similar between the two methods, according to Thanh […]
Early DAPT Improves Outcomes for Strokes With No Other Tx Options
DALLAS — Adding tirofiban (Aggrastat) to aspirin for dual antiplatelet therapy (DAPT) within 24 hours of acute ischemic stroke improved outcomes for patients who weren’t candidates for thrombolytic or endovascular treatment, according to a phase III trial from China. The combination of the glycoprotein IIb/IIIa inhibitor with aspirin shifted modified Rankin Scale (mRS) scores in […]